Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients with Hemiparesis in the Acute/subacute Phase (Month 1 to 4) (EarlyExo)

January 30, 2025 updated by: Wandercraft

The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.

This clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group.

The duration of the intervention period in both groups is 6 weeks.

  • For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.
  • For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).

The study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Créteil, France
        • Recruiting
        • Hôpitaux Universitaires Henri Mondor APHP, site Albert Chenevier
        • Contact:
        • Contact:
        • Contact:
          • Dr Caroline Colas, MD
      • Pionsat, France
        • Recruiting
        • Centre de Médecine Physique et de Réadaptation APAJH de Pionsat
        • Contact:
        • Contact:
        • Contact:
          • Dr Charles Orange, MD
  • Germany
      • Bad Aibling, Germany
        • Not yet recruiting
        • Schon Klinik
        • Contact:
        • Contact:
          • Dr Friedemann Müller, MD, M.Sc.
        • Contact:
          • Pr Klaus Jahn, MD
      • Berlin, Germany
        • Recruiting
        • Vivantes Klinikum Spandau
        • Contact:
        • Contact:
          • Dr Anatol Kivi, MD
        • Contact:
          • Pr Jörg Wissel, MD
  • Spain
      • Barcelona, Spain
        • Recruiting
        • Institut Guttmann
        • Contact:
        • Contact:
          • Dr Cristian Andres Figueroa Chacón, MD
        • Contact:
          • Dr Irene Sanchez Serrano, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • >18 years old
  • First clinically significant disability due to stroke
  • Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke
  • Functional Ambulation Category score (FAC) <2
  • Patient with health insurance
  • Informed and willing to sign an informed consent form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he/she can still be included if the signature can be done by an impartial witness.

Exclusion Criteria:

  • Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion
  • Recent fracture (< 3 months) or any therapy inducing secondary osteoporosis
  • Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion
  • Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA
  • Medical contra-indication to medium intensity physical strain
  • Orthostatic hypotension (loss of > 20 mmHg systolic BP after 3 minutes in standing position)
  • Uncontrolled seizures
  • Morphological contra-indications to the use of Atalante (as per user's manual)
  • Pregnant woman
  • Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention
  • Concurrent participation in another interventional trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exo group

During the 6-week intervention period, the Exo group will complete 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.

During sessions with the exoskeleton, the patient will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.

Conventional therapy corresponds to physiotherapy as part of post stroke standard of care of the center (tasks such as lower and upper limb practice, walking in parallel bars, etc., but this list is not exhaustive and depends on the practice of the therapists/centers).
Device: Use of the Atalante exoskeleton
Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
No Intervention: Control group
During the 6-week intervention period, the Control group will complete 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking recovery expressed by the proportion of patients reaching a Functional Ambulation Category (FAC) score of 4 or higher at the end of the intervention period, assessed without the exoskeleton.
Time Frame: End of the intervention period (week 6)
The FAC is a 6-item ordinal scale that classifies the level of support needed to walk safely, irrespective of the use of a lower extremity orthosis or walking aid, ranging from 0 (unable to walk without the assistance of two people) to 5 (independent walking on uneven surfaces and on stairs).
End of the intervention period (week 6)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking recovery expressed by the proportion of patients reaching a FAC score of 4 or higher at six months post stroke, assessed without the exoskeleton.
Time Frame: 6 months post stroke
6 months post stroke
Time to reach FAC score of 4 or higher
Time Frame: Day 1 (± 3 days), week 2 (± 3 days) and week 4 (± 3 days) after the beginning of the intervention period, end of the intervention period (Week 6 ± 3 days), discharge from hospital and 6 months post stroke (± 6 days).
Day 1 (± 3 days), week 2 (± 3 days) and week 4 (± 3 days) after the beginning of the intervention period, end of the intervention period (Week 6 ± 3 days), discharge from hospital and 6 months post stroke (± 6 days).
Change in walking speed measured with the 10 Meter Walk Test (10MWT)
Time Frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
The 10MWT is used to assess gait speed in meters/second over a short distance. Two tests are successively administered, barefoot, at comfortable then at maximal walking speed without walking aids. If a patient is unable to ambulate at all, a score of 0 m/s is documented.
Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
Changes in static and dynamic balance measured by the Berg Balance Scale (BBS)
Time Frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
The BBS is a subjective, ordinal scale that assesses the ability to safely balance and avoid falls, during a series of functional tasks. It is thus also a measure of the amount of assistance needed to perform these tasks safely. In most items, the subject must maintain a given position for a specified time or complete moving tasks of varying difficulty. Subject receives a score from 0-4 at each of the 14 items on the ability to meet these balance dimensions.
Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
Change in transfer time from wheelchair to toilet and back to wheelchair
Time Frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
The purpose is to record the time needed by the patient to do the transfer wheelchair /toilet seat/ wheelchair. Reduction of this time could mean an improvement of independence in daily life for stroke patients for whom transferring to the toilet is a common difficulty.
Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
Changes in maximal clinical muscle extensibility XV1 and maximal range of active motion XA against the resistance of the key lower limb muscles using the Five Step Assessment
Time Frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)

Measurements of XV1 and XA for soleus, gastrocnemius, gluteus maximus, hamstrings, vastus and rectus femoris muscles, using to the Five Step Assessment

  • XV1 is the angle of arrest at slow speed of stretch, corresponding to the passive range of motion against the resistance of the tested muscle.
  • XA is the maximal active range of motion against the resistance of the evaluated antagonist muscle.
Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
Changes in anxiety and depression scores using the Hospital and Depression scale (HAD)
Time Frame: Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
The HAD is a two-dimension self-administered questionnaire developed to identify depression and anxiety among physically ill patients. Identifying these disorders and the context in which they develop is interesting as motivation of the patient seems to have an important impact on his progression. It consists of 14 items rated with a score from 0-4, divided into 7 items for anxiety and 7 items for depression based on the concept of anhedonia.
Day 1 (± 3 days), end of the intervention period (Week 6 ± 3 days), discharge and 6 months post stroke (± 6 days)
Changes in perceived quality of life assessed by the Short Form-36 (SF-36)
Time Frame: Day 1 (± 3 days) and 6 months post stroke (± 6 days)

The SF-36 is a self-administered questionnaire that provides an evaluation of the generic Quality of Life. The version used is the RAND-36 Item Health Survey. There are 36 items (or questions) divided into eight domains:

Physical component:

  1. Physical functioning
  2. Role limitations due to physical problems
  3. Bodily pain

  4. General health perceptions

    Mental component:

  5. Social functioning
  6. General mental health
  7. Role limitations due to emotional problems
  8. Vitality Each item is answered by the subject with a Likert scale.
Day 1 (± 3 days) and 6 months post stroke (± 6 days)
Subject and Therapist satisfaction and willingness to continue training sessions
Time Frame: End of Week 1 (± 3 days), end of Week 3 (± 3 days) and end of the intervention period (Week 6 ± 3 days)
The subject is asked to answer two questions regarding his satisfaction and willingness to continue training sessions. The therapist answers one question on his satisfaction. The score of each question is evaluated with a 5-level Likert scale.
End of Week 1 (± 3 days), end of Week 3 (± 3 days) and end of the intervention period (Week 6 ± 3 days)
Perceived workload by the therapists conducting sessions assessed with the NASA Task Load Index
Time Frame: End of Week 1 (± 3 days) and end of the intervention period (Week 6 ± 3 days)

The NASA Task Load Index is a multidimensional, subjective scale that rates perceived workload in order to assess a task.There are six items, answered by the therapists after the therapy session:

  1. Mental demand
  2. Physical demand
  3. Temporal demand
  4. Effort
  5. Performance
  6. Frustration level The therapist gives his answers for the task "conducting a therapy session with the Atalante device" for patients of the Exo group, and for the task "conducting a conventional therapy session" for patients of the Control group.
End of Week 1 (± 3 days) and end of the intervention period (Week 6 ± 3 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wandercraft

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2023

Primary Completion (Estimated)

February 28, 2026

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

October 24, 2023

First Submitted That Met QC Criteria

October 24, 2023

First Posted (Actual)

October 30, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 30, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EarlyExo

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebrovascular Disorders

Clinical Trials on Use of the Atalante exoskeleton

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe